查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649516

荷尔蒙避孕药市场：预测（2025-2030）

Hormonal Contraceptives Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计荷尔蒙避孕药市场规模将从 2025 年的 78.36 亿美元增长到 2030 年的 101.84 亿美元，预测期内的复合年增长率为 5.38%。

荷尔蒙避孕药是使用合成荷尔蒙透过抑制排卵、增稠子宫颈黏液和改变子宫内膜来防止怀孕的避孕药。由于对计划生育和生殖健康咨询的需求不断增加，预计全球荷尔蒙避孕药的收益成长将会加速。这一趋势将荷尔蒙避孕定位为主要的计划生育解决方案，促进妇女健康和赋权，增加获得避孕的保护条例和政府倡议，并解决性行为感染传染病（STD）的发病率。此外，各大公司加大对新型避孕设备的开发投入、政府推出的各种旨在扩大避孕设备市场的倡议以及医疗相关人员认识的不断提高都是推动市场增长的主要因素。随着女性对避孕方法的了解越来越多，预计由意识主导的市场成长将从历史最低水准飙升。

荷尔蒙避孕药市场驱动因素

  • 采用有效的荷尔蒙避孕药：新型有效产品的推出推动了荷尔蒙避孕药的需求。几家主要企业正在投资先进的避孕技术。这种转变在美国等已开发国家尤其明显，NuvaRing 等产品在这些国家越来越受欢迎。这种避孕环具有与传统避孕药相当的功效，但使用方便，只需每三週更换一次。

主要区域趋势

  • 北美有望领先：预计预测期内北美地区的荷尔蒙避孕药市场将显着成长。这种增长可归因于现代化的医疗保健基础设施、高度的计划生育意识以及广泛的避孕选择。美国和加拿大凭藉其在医疗保健系统的强劲投资、广泛的研发机会以及在健康相关产品上的高消费者支出占据了市场的大部分份额。此外，政府计画和综合健康保险增加了获得荷尔蒙避孕的机会。

强大的医疗保健提供者网路和避孕技术的不断进步进一步支持了其在推动北美荷尔蒙避孕市场成长方面的领导地位。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔，涵盖主要地区和新兴地区。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 细分和区域分析，包括收益成长和预测国家
  • 公司概况（策略、产品、财务、主要发展等）

荷尔蒙避孕药市场区隔如下：

依产品类型

  • 口服避孕药
  • 注射
  • 皮肤贴剂
  • 子宫内避孕器 (IUD)
  • 避孕环
  • 事后紧急避孕药

依激素类型

  • 仅含黄体素的避孕药
  • 合併荷尔蒙避孕药

按通路

  • 医院
  • 零售
  • 在线的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 义大利
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 台湾
  • 其他的

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

5. 荷尔蒙避孕药市场（依产品类型）

  • 介绍
  • 口服避孕药
  • 注射避孕药
  • 皮肤贴剂
  • 子宫内避孕器 (IUD)
  • 避孕环
  • 事后紧急避孕药

6. 荷尔蒙避孕市场（依荷尔蒙类型划分）

  • 介绍
  • 仅含黄体素的避孕药
  • 合併荷尔蒙避孕药

7. 荷尔蒙避孕药市场（依分销管道）

  • 介绍
  • 医院
  • 零售
  • 在线的

8. 荷尔蒙避孕药市场（按地区）

  • 介绍
  • 北美洲
    • 依产品类型
    • 依激素类型
    • 按分销管道
    • 按国家
  • 南美洲
    • 依产品类型
    • 依激素类型
    • 按分销管道
    • 按国家
  • 欧洲
    • 依产品类型
    • 依激素类型
    • 按分销管道
    • 按国家
  • 中东和非洲
    • 依产品类型
    • 依激素类型
    • 按分销管道
    • 按国家
  • 亚太地区
    • 依产品类型
    • 依激素类型
    • 按分销管道
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Bayer AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • Mylan NV
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Church & Dwight, Co., Inc.
  • Ansell LTD.
  • Mayer Laboratories
  • The Female Health Company
  • Allergan plc
  • Afaxys, Inc.
  • Agile Therapeutics
  • Novartis AG
  • Prega International
简介目录
Product Code: KSI061617281

The hormonal contraceptives market is projected to grow at a CAGR of 5.38% over the forecast period, increasing from US$7.836 billion in 2025 to US$10.184 billion by 2030.

Hormonal contraception refers to contraceptive pills that utilize synthetic hormones to prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining. The growth of global revenues in hormonal contraception is expected to accelerate due to the rising demand for family planning and reproductive health counseling. This trend positions hormonal contraception as a leading solution for family planning, fostering women's health and empowerment, increasing protective regulations and government initiatives for contraceptive access, and addressing the incidence of sexually transmitted diseases (STDs). These factors collectively create pressure to adhere to preventive measures.Additionally, increased investments from major players in developing new contraceptive devices, various government initiatives aimed at expanding the contraceptive market, and heightened awareness among medical professionals are significant drivers of market growth. As women become more informed about their options for preventing pregnancy, awareness-driven market growth is anticipated to rise rapidly from a previously low base.

Drivers of the Hormonal Contraceptives Market

  • Introduction of Effective Hormonal Contraceptives: The demand for hormonal contraceptives is being driven by the introduction of novel and effective products. Several leading companies are investing in advanced technologies for contraceptive solutions. This shift has been particularly notable in developed countries like the United States, where products such as the NuvaRing have gained popularity. The vaginal ring offers comparable efficacy to traditional contraceptive pills but is user-friendly and only requires replacement every three weeks.

Key Geographical Trends

  • North America Expected to Lead: The North American region is projected to experience significant growth in the hormonal contraceptives market during the forecast period. This growth can be attributed to a modern healthcare infrastructure, high awareness of family planning, and a wide range of available contraceptive options. The U.S. and Canada hold substantial shares of the market due to robust investments in healthcare systems, extensive research and development opportunities, and considerable consumer spending on health-related products. Furthermore, government programs and comprehensive health insurance coverage enhance access to hormonal contraceptives.

The strong network of healthcare institutions and ongoing advancements in contraceptive technology further support North America's leadership in promoting growth within the hormonal contraception market.________________________________________

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Hormonal contraceptives Market has been segmented as following:

By Product Type

  • Oral Contraceptives
  • Injectable Contraceptive
  • Skin Patches
  • Intrauterine Devices (IUDs)
  • Vaginal Rings
  • Emergency Contraceptive Pills

By Hormone Type

  • Progestin-Only Contraceptives
  • Combined Hormonal Contraceptives

By Distribution Channel

  • Hospital
  • Retail
  • Online

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific Region
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HORMONAL CONTRACEPTIVES MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Oral Contraceptives
  • 5.3. Injectable Contraceptive
  • 5.4. Skin Patches
  • 5.5. Intrauterine Devices (IUDs)
  • 5.6. Vaginal Rings
  • 5.7. Emergency Contraceptive Pills

6. HORMONAL CONTRACEPTIVES MARKET BY HORMONE TYPE

  • 6.1. Introduction
  • 6.2. Progestin-Only Contraceptives
  • 6.3. Combined Hormonal Contraceptives

7. HORMONAL CONTRACEPTIVES MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Retail
  • 7.4. Online

8. HORMONAL CONTRACEPTIVES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Hormone Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Hormone Type
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Hormone Type
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. France
      • 8.4.4.3. Germany
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Hormone Type
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Hormone Type
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Bayer AG
  • 10.2. Pfizer, Inc.
  • 10.3. Teva Pharmaceutical Industries Limited
  • 10.4. Mylan N.V.
  • 10.5. Johnson & Johnson
  • 10.6. Merck & Co., Inc.
  • 10.7. Church & Dwight, Co., Inc.
  • 10.8. Ansell LTD.
  • 10.9. Mayer Laboratories
  • 10.10. The Female Health Company
  • 10.11. Allergan plc
  • 10.12. Afaxys, Inc.
  • 10.13. Agile Therapeutics
  • 10.14. Novartis AG
  • 10.15. Prega International